Welcome to our dedicated page for Tenon Medical news (Ticker: TNON), a resource for investors and traders seeking the latest updates and insights on Tenon Medical stock.
Tenon Medical, Inc. (TNON) delivers innovative solutions for sacroiliac joint disorders through its Catamaran™ System. This page provides authorized updates on clinical advancements, regulatory milestones, and strategic developments directly from the company and verified sources.
Investors and medical professionals will find comprehensive coverage of FDA clearances, peer-reviewed study results, and partnership announcements. Our curated news collection features earnings reports, product launch details, and analysis of market expansion efforts in minimally invasive spine technology.
Key updates include progress in post-market clinical studies, intellectual property developments, and educational initiatives for surgeons. All content undergoes strict verification to ensure alignment with financial disclosure regulations and medical accuracy standards.
Bookmark this page for real-time updates on TNON's pioneering work in SI joint fusion technology. For direct access to corporate filings and investor resources, visit the official Tenon Medical website through our verified links.
Tenon Medical, Inc. (NASDAQ:TNON) announced plans to release its financial results for Q1 2023, concluding on March 31, 2023, after market close on May 9, 2023. A conference call will follow at 4:30 p.m. Eastern Time to discuss the results, including a Q&A session. Investors can join the call via dial-in numbers: 1-888-886-7786 (USA) or 1-416-764-8658 (International). The audio will be available for playback until May 23, 2023. Tenon Medical focuses on the Catamaran™ SI Joint Fusion System, which offers a less invasive approach to treat sacroiliac disorders. The company is set for a national launch of this system, targeting a significant market opportunity.
Tenon Medical (NASDAQ:TNON) reported a transformative year, concluding with a 423% revenue increase in Q4 2022, totaling $277,000, and a full-year revenue of $691,000, up 332%. Surgical procedures using the Catamaran System surged 386% in Q4 and 361% for the year. Despite these gains, the company reported a gross loss of $(207,000) in Q4 and $(641,000) for 2022. Operating losses jumped to $7.9 million in Q4 and $18.7 million for the year, impacted by a $3.6 million charge related to the termination of a national distribution agreement. Cash reserves stood at $8.6 million as of year-end, supporting ongoing operations.
Tennon Medical (NASDAQ:TNON) has successfully treated its first patient in the clinical study for the Catamaran SI Joint Fusion System. Conducted by Dr. Mark H. Stouffer at Zion Surgery Center on November 14, 2022, the study aims to evaluate the long-term effectiveness of this innovative system in addressing sacroiliac joint disorders. Patients will be monitored for pain scores and fusion rates over 24 months. The Catamaran design is expected to enhance patient outcomes by stabilizing the joint and facilitating fusion.
Tenon Medical reported a 197% increase in revenue year-over-year for Q3 2022, totaling $208,000. The company launched its Catamaran SI Joint Fusion System at the North American Spine Society meeting, engaging healthcare professionals with workshops and technical exhibits. Operating losses rose to $3.3 million, with a net loss of $3.2 million, compared to losses of $2.1 million and $2.3 million in Q3 2021. The company's cash reserves stand at $12.5 million, expected to support future growth initiatives.
Tenon Medical, Inc. (NASDAQ:TNON) has announced its participation in two upcoming investment conferences. The Q4 Investor Summit will take place on November 14-15, 2022, with CEO Steven Foster and CFO Steven Van Dick presenting on November 15 at 9:30 a.m. Eastern Time. A webcast of this presentation will be available. The company will also participate in the Benchmark 11th Annual Discovery One-on-One Investor Conference on December 1, 2022. Management will be available for one-on-one meetings, and interested parties can contact investor relations.
